Changing Lives, One Patient at a Time
Changing Lives, One Patient at a Time
Sucraid®
(sacrosidase)
Oral Solution
VISIT PRODUCT SITE
Ethamolin®
(ethanolamine
oleate)
Injection 5%
VISIT PRODUCT SITE
Gimoti®
(metoclopramide) nasal spray
BOXED WARNING: TARDIVE DYSKINESIA
- Metoclopramide, including GIMOTI®, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder. In patients treated with metoclopramide, including GIMOTI®, the risk of developing TD increases with duration of treatment and total cumulative dosage.
- GIMOTI® is contraindicated in patients with a history of TD.
- Use GIMOTI® for the shortest duration of treatment and periodically reassess the need for continued treatment.
- Immediately discontinue GIMOTI® in patients who develop signs or symptoms of TD.
- Avoid a total duration of treatment with metoclopramide products, including GIMOTI®, for longer than 12 weeks. If longer-term use is unavoidable, routinely monitor for signs and symptoms of TD.
QOL Medical
QOL Medical is a specialty biopharmaceutical company dedicated to improving each patient’s life. We focus on solving complex, rare disease challenges with elegant solutions and want to change the world, one patient at a time.
QOL Medical was founded in 2003 to focus on the commercialization of orphan products for underserved markets. We provide expanded clinical awareness and patient access for the treatment of rare and orphan diseases. The company currently markets three FDA-approved products: Sucraid® (sacrosidase) Oral Solution, Ethamolin® (ethanolamine oleate) Injection, 5% and Gimoti® (metoclopramide) nasal spray.
Explore More
Sucraid® (sacrosidase) Oral Solution
Manufacturing Facility
1/5